ArticleCureus2025
Optic Neuritis Following Nivolumab Treatment for Metastatic Melanoma: A Case Report and Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have revolutionized the treatment of melanoma and other tumors; however, these novel drugs can trigger immune-related adverse events (irAEs), involving uncontrolled autoimmune cross-reactive damage to the brain, peripheral nerves, eyes, and connective tissue. We report an unusual case of optic neuritis and anterior uveitis following treatment with nivolumab, an anti-programmed cell death protein 1 inhibitor, in a 60-year-old Mexican woman with metastatic melanoma. We ruled out infectious, autoimmune, inflammatory, and neoplastic etiologies as the cause of optic neuritis. The patient experienced significant improvement in visual acuity and ocular pain after discontinuing nivolumab and initiating steroids with a tapered dosing regimen. When using checkpoint inhibitors, ocular and neurological symptoms should be monitored, and corticosteroid therapy can be considered a first-line treatment for patients with irAEs associated with nivolumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.